Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial

Next Previous
Trial Profile

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Registrational; Therapeutic Use
  • Sponsors BIAL - Portela C S.A.

    • Most Recent Events

    • 22 Jun 2021 Results assessing long-term efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for adults with focal seizures presented at the 7th Congress of the European Academy of Neurology
    • 29 Apr 2021 Status changed from active, no longer recruiting to completed.
    • 22 Apr 2021 Results assessing 10 years of post-marketing surveillance (PMS) safety data of eslicarbazepine acetate collected from randomised clinical trials in adults: BIA-2093-201, -301, -302 -303, -304 and -311, presented at the 73rd Annual Meeting of the American Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top